BARD1 and prostate carcinoma: Therefore, to gain additional insights regarding the role of PALB2 and BARD1 alterations on prostate tumor biology and therapy response, we modeled PALB2 and BARD1 loss in the prostate cancer cell lines DU145, LNCaP, and 22Rv1 (Supplementary Fig. 1).